Skip to main content

Table 1 Cost inputs per cycle per model health state

From: Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study

 

EVE plus EXE

BEV plus PACL

BEV plus CAPE

Total Pre-progression cost/cycle

   

Drug acquisition cost

2,447.75 €

3,806.42 €

3,510.97 €

Administration cost

0 €

260.89 €

115.95 €

Pre-treatment costs

0 €

82.58 €

36.69 €

Lab tests

42.82 €

52.41 €

48.25 €

Monitoring cost

52.34 €

52.34 €

52.34 €

Prophylactic treatment cost

-

274.72 €

416.77 €

Total post-progression cost/cycle

1,057.41 €

1,057.41 €

1,057.41 €

End-of-life cost

823.60 €

823.60 €

823.60 €

  1. EVE: everolimus; EXE: exemestane; BEV: bevacizumab; PACL: paclitaxel; CAPE: capecitabine